Key Launches Ahead But Vifor Plots More Pipeline Deals
Solid 2020 In Spite Of COVID-19 Impact
Executive Summary
Stefan Schulze, CEO of the Swiss iron deficiency and kidney disease specialist, tells Scrip that Vifor's reputation as a go-to industry partner should result in at least two more licensing deals or product acquisitions in 2021.
You may also be interested in...
Deal Watch: AI Specialist Biolojic Inks Diabetes Pact With Lilly, Autoimmune Tie-Up With Nektar
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.
EU: Vifor Tries Again With Avacopan Using ‘More Powerful’ Data
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.
Vifor Builds Its Kidney Disease Focus With $80m Angion Deal
Deal helps Vifor pursue goal of becoming a leader in kidney disease therapies.